| RARα |
Translocation leading to fusion with PML |
Acute promyelocytic leukemia |
Look et al. (1997) |
Designed TF (DBD only) mimicking RAR to compete at RAREs |
| AML1-ETO |
′′ |
M2 (acute myelogenous leukemia) |
Piazza et al. (2001) |
Designed TF (DBD only) mimicking AML1 to compete at AML1 sites |
| c-Myc |
Translocation leading to upregulated protein levels |
Burkitt’s lymphoma |
Gaidano and Dalla-Favera (2001) |
Designed TF repressor for Ig promoter |
| BCL6 |
′′ |
Non-Hodgkin’s lymphoma |
Gaidano and Dalla-Favera (2001) |
Designed TF that activates BCL6-repressed genes |
| WT1 |
Nonsense mutations leading to truncation |
Renal; soft tissue sarcoma |
Lee et al. (1999) |
Designed TF activator for WT1 targets |
| TLS/FUS and EWS |
Translocation leading to chimeric fusion protein |
Sarcoma |
Aman (1999) |
Unclear |
| p53 and Rb |
Loss-of-function mutations |
Many |
Hanahan and Weinberg (2000) |
Designed TF activator for Rb target genes |
